Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals. MarketWatch Nov 25, 2024, 3:43:00 PM. Cassava Sciences Shares Lower Premarket on $40 Million Penalty to ...

Cassava Sciences’ stock (NASDAQ: SAVA) plummeted on Monday by a staggering 85%. “The results are disappointing for patients and their families who are living with this disease and physicians ...

Get the latest news on Cassava Sciences stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SAVA performance ...

Investment Overview. The share price of Cassava Sciences (NASDAQ:SAVA) increased from ~$1, to $10 between 2019 and 2020, tread water between 2020 and 2021, had increased in value to >$120 by ...

Cassava Sciences Inc (NASDAQ: SAVA) shares are trading lower on above-average volume Wednesday. Despite Wednesday's fall, the stock is still up more than 50% since mid-August.

Cassava Sciences, Inc. reported $121.1m of cash and a net loss of $(97.2m) for the year 2023. The company's research and development expenses increased to $89.4m in 2023.

Shares of Cassava Sciences (SAVA 2.83%) skyrocketed in the first half of 2021. The biotech's share price ran up 1,152% from the first of January to the end of June.

Investing in Cassava Sciences (NASDAQ:SAVA) makes sense based on its fundamental financial position, but it remains a gamble. The company has run up against serious allegations in pursuit of Food ...

After surging from $7 per share to around $120 per share this year, Cassava Sciences (NASDAQ:SAVA) stock may not have room to make more “to the moon” moves higher. Source: Atthapon Raksthaput ...

The market's been in love with Cassava Sciences (SAVA 2.83%) all year, but it's definitely a rocky relationship. The stock soared from $8 a share back in January to $126 on Aug. 12.